grant
Biomarker Reference Laboratory
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 20 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025Active Follow-upAddressAssayBioassayBioinformaticsBiological AssayBiological MarkersBiometricsBiometryBiopsyBiostatisticsBlood SerumCancer DiagnosticsCancer TreatmentCertificationClassificationClinicalClinical ChemistryClinical InvestigatorClinical ResearchClinical StudyClinical TreatmentCollaborationsComputational toolkitDetectionDevelopmentDiagnosticDiagnostic MethodDiagnostic ProcedureDiagnostic TechniqueDiseaseDisorderEDRNEarly Detection Research NetworkEnrollmentFDA approvedFundingGenomicsGoalsGuidelinesHealthIndustrializationIndustryInstitutionInternationalKnowledgeLaboratoriesLeadershipLicensingMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMalignant neoplasm of prostateMalignant prostatic tumorMedicalMissionMorbidityMorbidity - disease rateNational Detection Research NetworkNumerical valueOvarianOvary CancerPathologyPatient MonitoringPatient TriagePerformancePhysiciansPopulation SurveillancePrincipal InvestigatorProceduresProductivityProstateProstate CAProstate CancerProstate GlandProstate malignancyProstatic GlandProteomicsPublic Health SurveillancePublicationsQuality ControlROC AnalysesROC CurveResearchResearch DesignResearch ResourcesResourcesScientific PublicationScientistScreening for cancerSerumSpecificityStudy TypeSurveillance ProgramSystematicsTechnologyTestingTranslatingTranslationsTreatment outcomeUniversitiesUrineUrologyValidationWorkactive followupanti-cancer therapyassay developmentbio-markersbiologic markerbiomarkerbiomarker arraybiomarker discoverybiomarker evaluationbiomarker identificationbiomarker panelbiomarker performancebiomarker utilitybiomarker validationcancer biomarkerscancer diagnosiscancer markerscancer therapycancer typecancer-directed therapyclinical assay developmentclinical epidemiologyclinical interventionclinical practiceclinical significanceclinical therapyclinically significantcomputational toolboxcomputational toolscomputational toolsetcomputer based predictioncomputerized toolsdesigndesigningdevelopmentaldiagnostic assayearly cancer detectionenrollexperiencefollow upfollow-upfollowed upfollowupidentification of biomarkersidentification of new biomarkersimprovedin-vitro diagnosticsindexinginnovateinnovationinnovativemarker evaluationmarker identificationmarker panelmarker validationmortalitymultidisciplinarynon-invasive monitornoninvasive monitorovarian cancerover-treatmentovertreatmentpatient populationpotential biological markerpotential biomarkerpredictive modelingproduct developmentprogression riskquality assurancereceiver operating characteristic analysesreceiver operating characteristic curveresearch studyscreening cancer patientsstudy designsuccesstech developmenttechnology developmenttissue biomarkerstranslationtrial regimentrial treatmenttumorvalidation studiesvalidations
Description preview
Our proposed EDRN BRL, which is located within the Clinical Chemistry Division (CCD) of the Johns Hopkins
Medical Institutions, will be an integral part of the BCC. The BRL will continue to serve as a network resource for
clinical and laboratory validation of biomarkers, which includes technological development and assay refinement,
as well as…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click